KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gilead Sciences (GILD) Non Operating Income (2016 - 2026)

Gilead Sciences filings provide 17 years of Non Operating Income readings, the most recent being $349.0 million for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 1097.14% to $349.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $798.0 million, a 11300.0% increase, with the full-year FY2025 number at $798.0 million, up 13200.0% from a year prior.
  • Non Operating Income hit $349.0 million in Q4 2025 for Gilead Sciences, down from $569.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $569.0 million in Q3 2025 to a low of -$369.0 million in Q1 2021.
  • Median Non Operating Income over the past 5 years was -$53.5 million (2023), compared with a mean of -$10.8 million.
  • Biggest five-year swings in Non Operating Income: skyrocketed 3030.0% in 2023 and later tumbled 460.44% in 2025.
  • Gilead Sciences' Non Operating Income stood at $57.0 million in 2021, then plummeted by 117.54% to -$10.0 million in 2022, then skyrocketed by 3030.0% to $293.0 million in 2023, then plummeted by 111.95% to -$35.0 million in 2024, then soared by 1097.14% to $349.0 million in 2025.
  • The last three reported values for Non Operating Income were $349.0 million (Q4 2025), $569.0 million (Q3 2025), and $208.0 million (Q2 2025) per Business Quant data.